Quick Answer
TELA Bio, Inc. reported Research And Development Expense of $9.22 million for the year ending 2025.
- TELA Bio, Inc. showed an increase of +4.6% in Research And Development Expense from 2024 to 2025.
- This data is from TELA Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $1.04 million | Q1 2019: $1.66 million | Q2 2019: $1.06 million | Q3 2019: $516.0 thousand | Q1 2020: $912.0 thousand | Q2 2020: $979.0 thousand | Q3 2020: $1.20 million | Q1 2021: $1.68 million | Q2 2021: $1.93 million | Q3 2021: $1.41 million | Q1 2022: $2.01 million | Q2 2022: $2.10 million | Q3 2022: $2.10 million | Q1 2023: $2.05 million | Q2 2023: $2.51 million | Q3 2023: $2.37 million | Q1 2024: $2.39 million | Q2 2024: $2.32 million | Q3 2024: $2.07 million | Q1 2025: $2.54 million | Q2 2025: $2.20 million | Q3 2025: $2.35 million.
- Over the full 9 years of available data (2017 to 2025), TELA Bio, Inc.'s Research And Development Expense has grown by 59.4%.
- Historical annual values: Fiscal year 2025: $9.22 million | Fiscal year 2024: $8.81 million | Fiscal year 2023: $9.62 million | Fiscal year 2022: $8.94 million | Fiscal year 2021: $6.74 million | Fiscal year 2020: $4.26 million | Fiscal year 2019: $4.15 million | Fiscal year 2018: $4.34 million | Fiscal year 2017: $5.79 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: